Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2413591
Max Phase: Preclinical
Molecular Formula: C13H14N2O3
Molecular Weight: 246.27
Molecule Type: Small molecule
Associated Items:
ID: ALA2413591
Max Phase: Preclinical
Molecular Formula: C13H14N2O3
Molecular Weight: 246.27
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN1C(=O)[C@@H]2C[C@@H](O)CN2C(=O)c2ccccc21
Standard InChI: InChI=1S/C13H14N2O3/c1-14-10-5-3-2-4-9(10)12(17)15-7-8(16)6-11(15)13(14)18/h2-5,8,11,16H,6-7H2,1H3/t8-,11+/m1/s1
Standard InChI Key: LUUAEXQOUOZTRB-KCJUWKMLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 246.27 | Molecular Weight (Monoisotopic): 246.1004 | AlogP: 0.24 | #Rotatable Bonds: 0 |
Polar Surface Area: 60.85 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 13.80 | CX Basic pKa: | CX LogP: -0.46 | CX LogD: -0.46 |
Aromatic Rings: 1 | Heavy Atoms: 18 | QED Weighted: 0.71 | Np Likeness Score: 0.03 |
1. Addla D, Jallapally A, Kanwal A, Sridhar B, Banerjee SK, Kantevari S.. (2013) Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors., 21 (15): [PMID:23777825] [10.1016/j.bmc.2013.05.031] |
Source(1):